↓ Skip to main content

Dove Medical Press

Article Metrics

The dexmedetomidine concentration required after remifentanil anesthesia is three-fold higher than that after fentanyl anesthesia or that for general sedation in the ICU

Overview of attention for article published in Therapeutics and Clinical Risk Management, October 2014
Altmetric Badge

Mentioned by

twitter
1 tweeter
facebook
1 Facebook page

Citations

dimensions_citation
2 Dimensions

Readers on

mendeley
22 Mendeley
Title
The dexmedetomidine concentration required after remifentanil anesthesia is three-fold higher than that after fentanyl anesthesia or that for general sedation in the ICU
Published in
Therapeutics and Clinical Risk Management, October 2014
DOI 10.2147/tcrm.s67211
Pubmed ID
Authors

Takayuki Kunisawa, Kazuhiro Fujimoto, Atsushi Kurosawa, Michio Nagashima, Koji Matsui, Dai Hayashi, Kunihiko Yamamoto, Yuya Goto, Hiroaki Akutsu, Hiroshi Iwasaki

Abstract

The general dexmedetomidine (DEX) concentration required for sedation of intensive care unit patients is considered to be approximately 0.7 ng/mL. However, higher DEX concentrations are considered to be required for sedation and/or pain management after major surgery using remifentanil. We determined the DEX concentration required after major surgery by using a target-controlled infusion (TCI) system for DEX.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 22 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 22 100%

Demographic breakdown

Readers by professional status Count As %
Other 5 23%
Researcher 4 18%
Student > Ph. D. Student 3 14%
Student > Master 2 9%
Student > Bachelor 2 9%
Other 5 23%
Unknown 1 5%
Readers by discipline Count As %
Medicine and Dentistry 12 55%
Pharmacology, Toxicology and Pharmaceutical Science 3 14%
Nursing and Health Professions 2 9%
Unspecified 1 5%
Immunology and Microbiology 1 5%
Other 1 5%
Unknown 2 9%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 October 2014.
All research outputs
#9,993,258
of 12,485,238 outputs
Outputs from Therapeutics and Clinical Risk Management
#764
of 922 outputs
Outputs of similar age
#154,851
of 229,860 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#6
of 6 outputs
Altmetric has tracked 12,485,238 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 922 research outputs from this source. They receive a mean Attention Score of 4.1. This one is in the 7th percentile – i.e., 7% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 229,860 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 17th percentile – i.e., 17% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one.